Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
The common stock described are being offered by Seres pursuant to a
shelf registration statement on Form S-3 (No. 333-216735), including a
prospectus, which was declared effective by the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467
Vice President, Investor Relations and Corporate Communications